# CNS colour table

| **Disease Name** | **Organisms** | **Identification Feature/Morphological Detail** | **Biotype and method of typing** | **Virulence Factors** | **Steps in Pathogenesis and Transmission** | **Toxins and it's mechanism of action** | **Clinical Manifestations** | **Specimen Collection and Transport** | **Microscopy and Smear Findings/Special Stains** | **Culture Media/Methods or Motility** | **Identification and Typing Methods** | **Detection Methods-Automated and Conventional** | **Treatment** | **Vaccines** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Acute Bacterial (Pyogenic) Meningitis | Overall: **Streptococcus pneumoniae** (~50%), **Neisseria meningitidis** (~25%), **Streptococcus agalactiae** (~15%), **Listeria** (~10%), **Haemophilus influenzae** (<10%). Neonates: S. agalactiae, E. coli, Klebsiella, L. monocytogenes. | Varies by organism. Characterized by elevated polymorphonuclear cells (neutrophils) in CSF. | - | Varies by organism (e.g., capsular polysaccharides). | **Transmission:** Person-to-person via respiratory droplets. **Routes of Infection:** 1. **Hematogenous spread** (most common). 2. **Direct spread** from otitis media, sinusitis. 3. **Anatomical defect** in CNS (trauma, surgery). **Pathogenesis:** Breach in the **blood-brain barrier (BBB)** by disrupting tight junctions or transport within phagocytes. | - | Incubation Period: 4 days (range 2-10). **Symptoms:** Fever, vomiting, intense headache, altered consciousness, photophobia. **Signs of meningism:** - **Nuchal rigidity** (stiff neck). - **Kernig's sign:** Inability to straighten leg when hip is flexed to 90°. - **Brudzinski's sign:** Passive neck flexion causes spontaneous hip and knee flexion. **In infants:** Slower onset, nonspecific signs, fever, irritability, bulging fontanelle. | **CSF:** Collected by lumbar puncture into 3 sterile containers. Transport immediately; if delay is expected, keep at 37°C (do not refrigerate). **Blood Culture:** Collected in automated blood culture bottles. | **CSF Analysis:** - Pressure: Highly elevated (>180 mm of water). - Leukocytes: 100-10,000/mm³, predominantly neutrophils. - Protein: >45 mg/dL (markedly increased). - Glucose: <40 mg/dL (markedly diminished or absent). **Gram Stain:** Heaped smear of centrifuged CSF deposit. Morphology gives preliminary clue. | Enriched media (Chocolate agar, Blood agar) and differential media (MacConkey agar). Incubate at 37°C in a candle jar (5% CO2) for 48 hours. **Enriching:** Inoculate into BHI broth or blood culture bottles. | Based on colony morphology, biochemical tests, and serogrouping specific to the isolated organism. | **Antigen Detection (CSF/Urine):** Latex agglutination for capsular antigens; Immunochromatographic test (ICT) for S. pneumoniae C-polysaccharide in urine. **Molecular:** Multiplex PCR (e.g., **BioFire FilmArray**) for simultaneous detection of 14 common agents. | **Empirical:** - Adult: IV cefotaxime/ceftriaxone + vancomycin (+ IV ampicillin if Listeria suspected). - Neonates: IV ampicillin + gentamicin. **Supportive:** IV dexamethasone to reduce intracranial pressure. **Definitive:** Based on culture and susceptibility results. | Available for S. pneumoniae, N. meningitidis, and H. influenzae type b. Widespread vaccination reduces incidence. |
| Pneumococcal meningitis | Streptococcus pneumoniae (pneumococcus) | Gram-positive diplococci, flame or lanceolate-shaped, with a clear halo (capsulated). | - | Capsular polysaccharide, C-carbohydrate antigen, pneumolysin, autolysin. | Spread from nasopharynx commensals, causing otitis media or pneumonia, then via bloodstream (bacteremia) to meninges. | **Pneumolysin:** - **Autolysin (lytA gene):** - | Leading cause of meningitis in adults (>20 years). **Risk factors:** Pneumococcal pneumonia, otitis media, alcoholism, diabetes, splenectomy, head trauma. Mortality rate is high (~20%). | CSF, Blood. | Gram-positive, lanceolate-shaped diplococci on CSF Gram stain. | α-hemolytic colonies on blood agar (draughtsman-shaped or carrom coin appearance). | Bile soluble, ferments inulin, sensitive to optochin. | **Antigen detection:** In urine using ICT. **Molecular:** PCR for **lytA**, **ply**, and **psaA** genes. | Refer to Pyogenic Meningitis Treatment. | (Discussed in detail in Chapter 61) |
| Meningococcal meningitis | Neisseria meningitidis (meningococcus) | Gram-negative diplococci, capsulated, with adjacent sides flattened (lens or half-moon shaped). Exist in both intra- and extracellular forms. | **Serogrouping:** Based on capsular polysaccharide. 13 serogroups, with A, B, C, X, Y, W causing most invasive disease. | **Capsular polysaccharide** (principal factor), Outer membrane proteins, **LPS (endotoxin)**, IgA proteases, transferrin binding proteins, adhesins. | **Transmission:** Droplet inhalation. Portal of entry is nasopharynx. **Spread to meninges:** 1. Hematogenous route (most common). 2. Direct spread along olfactory nerve. 3. Conjunctiva (rarely). | **Endotoxin (LPS):** Induces inflammatory mediators, damages vascular endothelium, leading to increased permeability (shock), intravascular thrombosis (**DIC**), and myocardial dysfunction. | Affects young children (3-5 years). **Rashes:** Non-blanching petechial or purpuric rash (>80% cases). **Waterhouse-Friderichsen syndrome:** Severe form with large purpuric rashes, shock, DIC, bilateral adrenal hemorrhage. **Postmeningococcal reactive disease:** Immune complex-mediated arthritis, rash, iritis 4-10 days later. | CSF, Blood, Nasopharyngeal swabs, pus/scrapings from rashes. Transport swabs in Stuart's medium. | Gram-negative, lens-shaped diplococci on CSF smear. | Non-hemolytic colonies on blood agar. Selective media: **Thayer Martin** or **New York City medium** for swabs. | Catalase and oxidase positive. Ferments glucose and maltose (not sucrose). **Serogrouping:** Slide agglutination serogrouping (SASG) test. | **Molecular:** PCR for **ctrA** (capsule transport) and **sodC** genes. | **Drug of choice:** 3rd-gen cephalosporins (ceftriaxone, cefotaxime) for 7 days. **Chemoprophylaxis (for close contacts):** Ceftriaxone (single IM dose), rifampicin, or ciprofloxacin. | **Polysaccharide vaccine:** Bivalent (A, C) or Quadrivalent (A, C, Y, W). Poorly immunogenic in children <2-3 years. **Conjugated vaccine:** Available, provides better immunity in young children. **Recombinant vaccine (MenB):** For serogroup B, contains four recombinant proteins. |
| Haemophilus influenzae meningitis | Haemophilus influenzae, especially serotype b (Hib). | Pleomorphic gram-negative coccobacilli, capsulated. | Six capsular serotypes. Serotype b (Hib) is the most virulent. | **Capsular polysaccharide** (most important virulence factor), inhibits phagocytosis. | Causes pneumonia, which spreads by hematogenous route to cause meningitis. | - | Mainly occurs in children < 2 years of age. **Complication:** Subdural effusion (common), leading to seizures or hemiparesis. High mortality if untreated, neurologic sequelae in survivors. | CSF, blood. | Pleomorphic gram-negative coccobacilli on CSF Gram stain. | Grows on chocolate agar. Shows **satellitism** on blood agar with S. aureus streak line. | Requires both X and V factors for growth. Disk test shows growth around combined XV disk. | **Molecular:** PCR for conserved capsular gene **bexA**. | (Discussed in Chapter 61) | Incidence dramatically reduced after start of effective vaccination. (Hib vaccine) |
| Listeriosis (CNS infection) | Listeria monocytogenes | Gram-positive short bacilli, often confused with diphtheroids. | Most human infections caused by serotypes 1/2a, 1/2b, and 4. | **Listeriolysin O** (for phagosome lysis), ability to cause host cell actin polymerization. | **Transmission:** Most commonly through contaminated food (coleslaw, soft cheese, deli meats). Vertical transmission (mother to fetus). **Pathogenesis:** Intracellular survival and **direct cell-to-cell spread** via listeriopods, mediated by actin polymerization. | - | Meningitis in neonates and elderly (>60 years). **Risk factors:** Extremes of age, pregnancy, immunosuppression, use of proton pump inhibitors. **Neonatal Listeriosis:** - **Early-onset (<5 days):** Acquired from maternal genital flora. Presents as neonatal sepsis. High mortality (up to 50%). Granulomatosis infantiseptica is a rare severe form. - **Late-onset (>5 days):** Acquired from environment. Presents as neonatal meningitis. Lower mortality (<10%). **Pregnant women:** Flu-like symptoms, bacteremia. Can cause abortion, preterm delivery. | CSF, Blood. For food/environmental samples. | Gram-positive short bacilli. CSF is predominantly lymphocytic, unlike other pyogenic meningitis. | **Differential motility:** Tumbling motility at 25°C, non-motile at 37°C. **Culture:** Grows on blood agar (β-hemolytic colonies). Selective media: **PALCAM agar**. | - | - | **Meningitis:** Ampicillin is drug of choice, for 2-3 weeks, combined with gentamicin for synergy. **Avoid:** Cephalosporins, chloramphenicol are not active in vivo. | - |
| Chronic Bacterial Meningitis | **Mycobacterium tuberculosis**, **Borrelia burgdorferi**, **Treponema pallidum**. Rare: Nocardia, Actinomyces, Brucella. Also partially treated pyogenic meningitis. | Varies by organism. | - | - | - | - | Persistence of signs and symptoms >4 weeks. **Cardinal features:** Persistent headache, neck/back pain, hydrocephalus, cranial neuropathies (facial weakness, vision loss), myelopathy or radiculopathy. | - | **CSF Analysis:** Persistent inflammatory response (WBC >5/μL), predominantly lymphocytic. | - | - | - | - | - |
| Tuberculous Meningitis (TBM) | Mycobacterium tuberculosis | Acid-fast bacilli (long, slender, beaded). | - | - | Results from **hematogenous spread** of primary or post-primary pulmonary TB. | - | Disease evolves over 1-2 weeks or longer. **Subtle onset:** Headache, slight mental changes, low-grade fever. **Acute evolution:** Severe headache, confusion, lethargy. **Frequent findings:** Cranial nerve paresis (especially ocular nerves), stroke. Progresses to coma, hydrocephalus. | CSF. | **CSF Analysis:** - Pressure: Moderately elevated. - Leukocytes: 10-500/mm³, mostly lymphocytic. - Protein: 100-500 mg/dL. - Glucose: 20-40 mg/dL (slightly decreased). **Cobweb coagulum** may form after 12 hrs. **Acid-fast staining:** Low sensitivity (10-40%). Staining cobweb gives better yield. | **Culture (Gold Standard):** Lowenstein-Jensen medium (4-8 weeks) or automated liquid culture (e.g., **MGIT**, 2-3 weeks). | - | **GeneXpert assay (automated real-time PCR):** Preferred initial test. Sensitivity up to 80%. Detects M. tuberculosis and rifampicin resistance. **Imaging:** CT/MRI may show hydrocephalus, abnormal enhancement of basal cisterns. | Invariably fatal if unrecognized. Start treatment immediately on positive **GeneXpert** result. Responds well to anti-tubercular therapy if started early. Adjunctive glucocorticoids may be used. | - |
| Neurosyphilis | Treponema pallidum | - | - | - | Tertiary form of syphilis, develops in ~10% of untreated patients. CNS invasion occurs early (first few weeks) followed by years of asymptomatic period. | - | **Asymptomatic neurosyphilis:** CSF abnormalities without clinical manifestations. **Meningeal syphilis:** Features of chronic meningitis. **Meningovascular syphilis:** Vasculitis of arteries leading to embolic stroke. **General paresis of insane:** Parenchymal damage with defects in personality, affect, reflexes, eye (**Argyll Robertson pupils**), sensorium, intellect, speech. **Tabes dorsalis:** Demyelination of posterior columns (ataxia, foot drop, etc). | CSF. | **CSF Analysis:** Increased lymphocytes (>5/µL) and increased protein (>45 mg/dL). | - | **CSF VDRL test:** Nontreponemal test. Highly specific, but low sensitivity. Diagnostic when reactive. **CSF FTA-ABS test:** Treponemal test. More reactive than VDRL, but may reflect passive transfer of serum antibody. A nonreactive test can rule out asymptomatic neurosyphilis. | **PCR-based tests:** Amplify T. pallidum specific genes (e.g., 47-kDa surface antigen). | Aqueous crystalline or procaine penicillin G for 10-14 days. Desensitization required for penicillin allergy. | - |
| Tetanus | Clostridium tetani | Obligate anaerobic, gram-positive bacillus with a terminal round spore (**drum stick appearance**). | - | Produces two exotoxins: tetanolysin and tetanospasmin. | **Transmission:** Enters through injury (abrasions, wounds), surgery, unhygienic deliveries (neonatal tetanus). Non-infectious (no person-to-person spread). Toxin is transported retrograde up the motor neuron to inhibitory neuron terminals. | **Tetanospasmin (Tetanus Toxin):** A neurotoxin. Binds to polysialoganglioside receptors on motor nerve terminals, gets internalized, and travels retrograde. It **prevents the presynaptic release of inhibitory neurotransmitters (glycine and GABA)**, leading to spastic muscle contraction. | Incubation period: 6-10 days. **First symptom:** Trismus (lockjaw). **Progression:** Descending spastic paralysis. Hands and feet are spared.  **Complications:** - **Risus sardonicus:** Sustained spasm of facial muscles (grinning). - **Opisthotonos:** Abnormal posture from extensor muscle spasm. - **Autonomic disturbance:** Tachycardia, blood pressure changes. | Excised tissue bits from necrotic depths of wounds. | Gram stain shows gram-positive bacilli with terminal round spores (drum stick appearance). Unreliable as cannot distinguish from non-pathogenic clostridia. | **Robertson cooked meat broth:** Turns meat particles black, produces foul odor (proteolytic). **Blood agar with polymyxin B:** Shows characteristic **swarming growth** under anaerobic conditions. | **Toxigenicity Test:** In vivo mouse inoculation test on serum/urine to demonstrate toxin production. | - | **Passive Immunization (Treatment of choice):** Human Tetanus Immunoglobulin (HTIG) or Antitetanus Serum (ATS). **Antibiotics:** Metronidazole is drug of choice. **Supportive:** Endotracheal intubation, anti-spasmodics (diazepam), beta-blockers, surgical debridement of wound. | **Active Immunization (Tetanus Toxoid - TT):** Available as monovalent (TT), combined (DPT, Td, Pentavalent). Given under National Immunization Schedule. |
| Viral Meningitis | **Enteroviruses** (>85% of cases). Others: Herpesviruses (HSV, VZV, EBV), Arboviruses, LCM virus, Mumps, HIV. | - | - | - | **Transmission:** Close contact with infected patients. Feco-oral for enteroviruses, arthropod vector for arboviruses. **Seasonality:** Late spring to fall. | - | Less severe than bacterial meningitis. Fever, headache (frontal/retro-orbital), stiff neck (milder), photophobia, nausea, vomiting. No seizures or profound confusion. | CSF, throat swabs, stool, blood, urine. | **CSF Analysis:** - Pressure: Normal or mildly elevated. - Leukocytes: 25-500/μL, typically lymphocytic (neutrophils may predominate in first 48h). - Protein: 20-80 mg/dL (normal or slightly elevated). - Glucose: Normal. - No organisms on Gram stain. | Viral culture sensitivity is generally poor. | - | **Molecular Methods (Gold Standard):** PCR of CSF for specific viral DNA/RNA. Multiplex PCR (e.g., **BioFire FilmArray**) available. **Antibody Detection:** Useful for less prevalent viruses like West Nile Virus. | Primarily symptomatic (analgesics, antipyretics). **Acyclovir** may benefit in HSV, severe EBV or VZV cases. Patients with HIV meningitis need HAART. | - |
| Coxsackievirus Infections (CNS) | Coxsackieviruses (Group A and B), family Picornaviridae. | - | Group A (serotypes 1-24) and Group B (serotypes 1-6), based on pathogenic potential in suckling mice. | - | **Transmission:** Feco-oral route, spread through nasal/throat secretions. | - | **Aseptic meningitis:** Caused by all Group B types and many Group A types (A7, A9 are most common). **Herpangina:** Febrile vesicular pharyngitis (Group A). **Hand-foot-and-mouth disease:** Oral ulcers, vesicular rashes on palms/soles (Coxsackievirus A16). **Pleurodynia (Bornholm disease):** Abrupt stabbing chest pain (Group B). **Myocarditis/Pericarditis:** (Group B). | Throat swabs, stool, CSF. | - | Isolation in tissue culture (CPE in 5-14 days). **Suckling mice inoculation (obsolete):** Group A causes flaccid paralysis; Group B causes spastic paralysis. | Serology to detect neutralizing antibodies. | PCR targeting specific genes (e.g., VP1) is highly useful, rapid, and sensitive. | Symptomatic treatment. | - |
| Poliomyelitis | Poliovirus (an enterovirus), family Picornaviridae. Wild poliovirus (WPV) and vaccine derived poliovirus (VDPV). | Small (28-30 nm), nonenveloped, spherical with icosahedral symmetry. Single-stranded positive sense linear RNA. Capsid has four viral proteins (VP1-VP4). | Three wild poliovirus strains (WPV1, WPV2, WPV3). WPV2 and WPV3 are eradicated. All natural cases now are WPV1. | - | **Transmission:** Feco-oral route (most common), respiratory droplets. **Pathogenesis:** Binds to **CD155 receptor**. Multiplies in intestinal epithelium, Peyer's patches. **Hematogenous spread** to CNS. Final target is motor nerve endings (anterior horn cells of spinal cord), leading to neuron degeneration and flaccid paralysis. | - | **Paralytic poliomyelitis (<1%):** Descending asymmetric acute flaccid paralysis (AFP). Proximal muscles affected earlier than distal. Leads to characteristic **tripod sign**. No sensory loss.  **Biphasic course** in children.  **Risk factors:** Tonsillectomy, IM injections. | Throat swabs (up to 3 weeks), rectal swabs/stool (up to 12 weeks). Transport frozen. Sewage testing for surveillance. | - | Isolation in primary monkey kidney cell lines. Cytopathogenic effects (CPE) appear in 3-6 days. | Isolated virus identified and serotyped by neutralization with specific antiserum. | **Antibody detection:** Rise in titer in paired sera by **neutralization test**. **Molecular:** Real-time multiplex RT-PCR from stool specimen. | - | **Injectable Polio Vaccine (IPV, Salk):** Inactivated, safer, but no herd immunity. Given as fractional dose (f-IPV) at 6 & 14 weeks in India. **Oral Polio Vaccine (OPV, Sabin):** Live attenuated, provides herd immunity, cheaper. Can cause VAPP and VDPV. Bivalent OPV (serotypes 1 and 3) used in India. |
| Arboviral Encephalitis (Japanese Encephalitis) | Japanese Encephalitis Virus (JEV), family Flaviviridae. | Enveloped virus, containing ssRNA. | - | - | **Vector:** Bite of **Culex** mosquito (e.g., **C. tritaeniorhynchus**). **Transmission Cycle:** Infects non-human hosts. Pigs are the **amplifier host**. Wading birds (Ardeid birds) are also hosts. Humans are dead-end hosts. | - | Incubation period 5-15 days. Shows **iceberg phenomenon** (subclinical to clinical ratio 1:300 to 1:1000). **Clinical Course:** 1. **Prodromal stage:** Febrile illness. 2. **Acute encephalitis stage:** Main cause of **Acute Encephalitis Syndrome (AES)** in India. Acute fever, mental confusion, seizures. 3. **Late stage:** Convalescence with permanent neurological deficits (up to 50%). | Blood, CSF. | **CSF Analysis:** Lymphocytic pleocytosis, mildly elevated protein, normal glucose. | - | - | **IgM capture antibody (MAC) ELISA:** Recommended method. Detects JE-specific IgM antibody in serum/CSF. **Molecular:** RT-PCR to detect JE virus specific envelope (E) gene in blood. | Supportive measures only. No specific antiviral drugs available. | **Live attenuated SA 14-14-2 vaccine:** Cell line-derived. Given to children in endemic districts in India. Two doses. **Inactivated JE vaccine:** Vero cell culture-derived. |
| Rabies | Rabies virus, family Rhabdoviridae. | **Bullet-shaped**, enveloped virus with peplomers (G-protein). Nucleocapsid has helical symmetry and negative-sense ssRNA. | **Street virus:** Freshly isolated strains, long incubation, produce Negri bodies. **Fixed virus:** Lab-adapted strains, short incubation, do not produce Negri bodies. | **Glycoprotein-G:** Binds to acetylcholine receptors, induces neutralizing antibodies. **Nucleoprotein-N:** Group-specific antigen, detected for diagnosis. | **Transmission:** Bite from rabid animal (99% from dogs). **Pathogenesis:** Virus replicates locally in muscle -> binds to nicotinic ACh receptors at NMJ -> travels via **retrograde fast axonal transport** to CNS -> disseminates in CNS (hippocampus, cerebellum) -> centrifugal spread via nerves to salivary glands, skin, cornea. | - | Incubation Period: 20-90 days. **1. Prodromal Phase:** Fever, malaise, paresthesia at wound site. **2. Acute Neurologic Phase:** - **Encephalitic (furious) rabies (80%):** Hyperexcitability, **hydrophobia**, **aerophobia**, autonomic dysfunction (foaming at mouth). - **Paralytic (dumb) rabies (20%):** Flaccid paralysis, starting in bitten limb. **3. Coma and Death:** Almost always fatal. | Hair follicles from nape of neck (most sensitive), corneal impression smear, saliva, skin biopsy, brain biopsies (postmortem). | **Negri Body Detection (Postmortem):** Pathognomonic. Intracytoplasmic eosinophilic inclusions in Purkinje cells (cerebellum) and pyramidal neurons (hippocampus). Stained by **Sellers stain** or H&E. | **Viral Isolation:** Intracerebral inoculation into suckling mice, or on cell lines (Mouse neuroblastoma, BHK). Viral growth detected by direct-IF. | **Antibody Detection (CSF/Serum):** By Mouse neutralization test (MNT), Rapid fluorescent focus inhibition test (RFFIT). CSF antibodies are significant. | **Antigen Detection (Gold Standard):** Direct immunofluorescence test (DFA) on hair follicles/corneal smear. **Viral RNA Detection:** RT-PCR is most sensitive and specific assay. | No specific treatment. Symptomatic care in isolation. Prognosis almost 100% fatal once symptoms appear. | **Post-exposure Prophylaxis (PEP):** Wound care, Rabies vaccine, and Rabies Immunoglobulin (RIG). **Vaccines:** Cell line derived non-neural vaccines (PCEC, P-Vero cell, HDC). Given by ID or IM route. |
| Human Prion Diseases (Creutzfeldt-Jakob Disease) | Prions (infectious protein particles). Designated PrPSc (Scrapie Prion Protein). | Lacks nucleic acid. Globular polypeptide, rich in β-structure, resistant to proteases. Aggregates as amyloid-like plaques. | - | - | **Mechanism:** Infectious PrPSc induces misfolding of normal cellular PrPC protein. Aggregated PrPSc are internalized by neurons, accumulate in cytoplasmic vacuoles, causing spongiform appearance and cell death. | - | Long incubation period (months to years). Rapid progression once symptoms start. **Manifestations:** Loss of muscle control, shivering, myoclonic jerks, tremors, rapidly progressive dementia. Death within 1 year. **Types of CJD:** - **Sporadic (sCJD, 85%):** Spontaneous misfolding. - **Familial (fCJD):** Hereditary. - **Iatrogenic (iCJD):** Contamination from medical procedures. - **Variant (vCJD):** Affects younger people (<30 yrs), linked to consuming beef with BSE prions. | Brain biopsy tissue. | **Neuropathological diagnosis:** Spongiform degeneration with lack of inflammatory response. | - | **Measurement of PrPSc:** Conformation dependent immunoassay is the definitive diagnostic tool. **Gene sequencing:** Sequencing the PRNP gene to identify mutations in familial forms. | **Abnormal EEG:** In late stage, shows high-voltage, triphasic sharp discharges. | No known effective therapy. | - |
| Naegleria fowleri Infections (PAM) | Naegleria fowleri (a free-living amoeba) | **Trophozoite:** Occurs as amoeboid form (20µm, lobular pseudopodia) and flagellated form. **Cyst:** 7-15µm, thick, smooth double wall. | - | Produces food cups (amoebostome), hemolytic proteins, cytolysins, phospholipase enzymes. | **Transmission:** Inhalation of water containing amoeboid form during swimming in warm fresh water. Invades nasal mucosa, cribriform plate, travels along olfactory nerve to brain. | Tissue destruction by direct ingestion of brain tissue and contact-dependent cytolysis. | **Primary Amoebic Meningoencephalitis (PAM):** Acute, suppurative, fulminant CNS infection. Affects healthy children/young adults. **Symptoms:** Initial changes in taste/smell, then headache, fever, stiff neck. Progresses to confusion, seizures. Mortality rate nearly 98%. | CSF (specimen of choice). Examine immediately, do not refrigerate. | **CSF analysis:** Thick, purulent, >20,000 pus cells/µL, elevated protein, reduced sugar (mimics bacterial meningitis). **Wet mount:** Shows motile amoeboid trophozoites. Cysts not seen in CSF. | **Culture:** On non-nutrient agar lawn cultured with E. coli. Naegleria feeds on bacteria, producing trails (**Trail sign**). | **Enflagellation test:** Amoeboid form transforms to pear-shaped flagellate form in distilled water. **Isoenzyme analysis:** For specific identification. | **Molecular:** Multiplex real-time PCR. **Direct fluorescent antibody staining** of centrifuged CSF. | No effective treatment available. Amphotericin B has some effect. Other drugs like rifampicin, miconazole, miltefosine also tried. | - |
| Acanthamoeba Infections (GAE) | Acanthamoeba species (e.g., A. astronyxis, A. castellanii) | **Trophozoite:** 30µm, with thorn/spine-like pseudopodia (**acanthopodia**). **Cyst:** 10-25µm, double walled, with an outer wrinkled ectocyst. No flagellated form. | - | Can act as a **Trojan horse** for bacteria like Legionella. | **Transmission:** Inhalation of aerosol with cysts/trophozoites. Primary sites are sinuses and lungs. Trophozoites reach CNS by **hematogenous route**. | - | **Granulomatous Amoebic Encephalitis (GAE):** Insidious onset, subacute to chronic course. **Risk factors:** Immunocompromised patients (e.g., HIV). **Pathology:** Focal granulomatous lesions in brain. **Symptoms:** Confusion, dizziness, nausea, headache, seizure, hemiplegia. | CSF, brain biopsy. | **CSF microscopy:** Trophozoites and occasionally cysts are seen. Differentiate from pus cells by motility. **Staining:** H&E or PAS stain on brain biopsy. **Calcofluor stain** for cysts. | Culture on non-nutrient agar with bacterial supplement, incubated at 30°C. Not readily isolated. | **IFAT** with specific antisera for speciation. | **Molecular:** Multiplex real-time PCR. **Imaging:** CT/MRI shows space-occupying or ring-enhancing lesions. | No therapies with proven efficacy. Combination therapy recommended: Pentamidine, an azole, sulfonamide, flucytosine. | - |
| Toxoplasma Encephalitis (TE) | Toxoplasma gondii | **Tachyzoite:** Crescent shaped, actively multiplying form. **Tissue cyst:** Resting stage with bradyzoites. Spherical in brain. **Oocyst:** Sexual form found in cats. | Three genotypes (I, II, III). | - | In HIV patients, TE occurs due to **reactivation of latent infection**. Develops when CD4+ count < 100/µL. Parasite directly invades brain tissue causing necrotizing encephalitis. | - | Most common presentation of toxoplasmosis in HIV-infected individuals.  **Areas involved:** Brainstem, basal ganglia, pituitary. **Symptoms:** Altered mental status, seizures, sensory abnormalities, focal neurologic findings. | Peripheral blood, body fluids, biopsy material from brain. | **Giemsa stain:** shows comma-shaped tachyzoites. **Histopathology:** Pseudocyst with tachyzoites or tissue cyst with bradyzoites (PAS positive). | Animal inoculation (mice) or tissue culture (HeLa, Vero cells). | Antibody detection is not reliable in immunocompromised patients. **IgE antibody:** Useful for TE in HIV patients. **Sabin-Feldman Dye Test:** Gold standard but rarely used. | **Molecular:** PCR to detect T. gondii DNA from blood/CSF. **Imaging:** CT or MRI shows multiple ring-enhancing lesions. | **Primary prophylaxis (CD4 <100/µL):** Trimethoprim-sulfamethoxazole. **Treatment/Secondary prophylaxis:** - (Text gives prophylaxis, not specific TE treatment drugs, but implies it's required). | - |
| Neurocysticercosis (NCC) | Larval stage (Cysticercus cellulosae) of Taenia solium. | Mature cysticercus: 5x8-10mm, yellowish white, contains a bladder-like sac with vesicular fluid and an inner growing scolex. | - | - | **Transmission:** Ingestion of T. solium eggs from contaminated food/water or by **autoinfection** (external or internal). Embryo (oncosphere) hatches, penetrates intestine, travels via circulation to brain and other tissues, developing into a cysticercus. | - | Most common parasitic CNS infection. Most common cause of adult-onset epilepsy worldwide. **Seizure (70%):** Most common manifestation. **Hydrocephalus:** Most common extra-parenchymal feature. **Other features:** Increased ICP, chronic meningitis, focal deficits. **Diagnostic Criteria:** Based on **Revised DelBrutto's Diagnostic Criteria** (2016) which uses clinical, imaging, immunological and epidemiological data. | Serum, CSF for serology. Biopsy of lesions. | **Histopathology/FNAC:** Can differentiate viable, necrotic, and calcified cysticerci. Cholesterol and Charcot-Leyden crystals may be seen. | - | **Antibody Detection:** - **ELISA:** Using crude extract or purified glycoprotein antigens. CSF ELISA is better. - **Western blot (EITB):** Uses LLGP antigenic fractions. Highly specific (100%). Presence of 1 to 7 Gp bands confirms diagnosis. | **Radiodiagnosis (Imaging):** CT and MRI are key. Shows number, location, stage of cysts. Live cysticerci are hypodense with hyperdense scolex. Ring enhancement indicates inflammation. **Antigen Detection:** By ELISA, useful for monitoring treatment. | **Antiparasitic agents:** Albendazole or Praziquantel for brain parenchymal lesions. **Symptomatic:** Antiepileptic drugs, glucocorticoids (to reduce inflammation). **Surgery:** For hydrocephalus (shunting) or ocular/spinal lesions. | Vaccines for porcine cysticercosis are under development. |
| Cryptococcal Meningitis | Cryptococcus neoformans, Cryptococcus gattii | Capsulated yeast. Gram-positive round budding yeast cells. | Two species, four serotypes (A, B, C, D). C. neoformans var. grubii (Serotype A), C. neoformans var. neoformans (Serotype D). C. gattii (Serotypes B and C). | **Polysaccharide capsule** (principal virulence factor, antiphagocytic), ability to produce **melanin** (via phenyl oxidase), phospholipase, urease. | **Transmission:** Inhalation of aerosolized yeast cells or basidiospores from soil (especially with avian excreta). **Pathogenesis:** Pulmonary infection followed by dissemination. CNS spread by direct migration across endothelium or carried inside macrophages as a "**Trojan horse**". | - | Presents as chronic meningitis. **Symptoms:** Headache, fever, sensory and memory loss, cranial nerve paresis, loss of vision. **Risk factors:** Advanced HIV (CD4 < 200/µL for C. neoformans), hematologic malignancies, transplant recipients. C. gattii affects immunocompetent individuals. | CSF, blood, skin scrapings. | **Negative Staining:** Modified **India ink** or nigrosin stain shows refractile clear capsule around yeast against a black background. **Other Stains:** Mucicarmine, Masson-Fontana. | Culture on SDA without antibiotics at 37°C. Produces mucoid, creamy white, yeast-like colonies. | **Confirmation of species:** Melanin production on Niger seed agar (brown colonies), growth at 37°C, positive urease test, assimilation of inositol and nitrate. | **Antigen Detection:** Latex agglutination test for capsular antigens in CSF/serum. Rapid and sensitive (95%). **Automated ID:** MALDI-TOF. | **HIV-infected CNS involvement:** Induction phase (2 weeks) with Amphotericin B + flucytosine, followed by oral fluconazole therapy. | - |